Talk:Unity Biotechnology

Request edit
As an employee of Unity Biotechnology, I am proposing two changes to the current description of the company based on publicly available information.

1- the page currently states that has a product "in Phase I clinical trials as of September 2018" (second paragraph) Actually, the Phase 1 trial was initiated in June 2018, as reported on FightAging.org. The company also issued a press release announcing the trial initiation. I propose that this date be updated accordingly to state "as of June 2018..." 2- the page states that "Unity Biotechnology is a startup biotechnology company that aims to develop drugs which target senescent cells with the aim of extending life span." (paragraph 1) As noted in the company's S-1 SEC filing, the company's mission is to "extend human healthspan" not life span. As such, I propose replacing "life span" with "healthspan" so that the sentence reads: "Unity Biotechnology is a startup biotechnology company that aims to develop drugs which target senescent cells with the aim of extending healthspan."Bluealg (talk) 21:30, 14 November 2018 (UTC)

Reply 14-NOV-2018

 * Healthspan is a neologism, so that lead statement has been omitted from the article, per MOS:NEO.  Spintendo   00:24, 15 November 2018 (UTC)

One proposed change
Jw126 (talk) 23:18, 26 January 2021 (UTC)
 * Information to be added or removed: Remove "Unity Biotechnology shares dropped over 60 per cent on August 17, 2020 after the company reported disappointing results from a clinical trial involving its lead drug candidate, UBX0101 in patients with moderate-to-severe painful osteoarthritis."
 * Explanation of issue: A single day stock price is unusual for Wikipedia. Should all stock price changes be included in Unity's Wikipedia page?
 * References supporting change: https://finance.yahoo.com/quote/ubx?ltr=1

I wouldn't say it's unusual to document a drop or rise in price that received significant coverage in reliable, independent sources. Nearlyevil665 (talk) 18:22, 3 February 2021 (UTC)
 * Their stock value as of today (30 March 2021) still has not recovered, and it trades at approximately half the price of that from before the UBX0101 clinical-trial announcement (USD 5.5 today vs USD 12.4 on 14 August 2020). We can wait and see if the stock recovers, a time when we can mark the loss as not signficant in the medium-term and remove the phrase from the article. In the meantime it can remain there unless other editors disagree. Ferkijel (talk) 10:29, 30 March 2021 (UTC)